Interview 33 - First-line targeted therapy for axial spondyloarthritis
Автор: Arthritis Broadcast Network
Загружено: 2025-02-28
Просмотров: 34
Описание:
Dr. Walter Maksymowych is a Professor in the Faculty of Medicine & Dentistry at the University of Alberta. He is co-founder and principal investigator the Spondyloarthritis Research Consortium of Canada (SPARCC).
Dr. Maksymowych joins ACE’s Kelly Lendvoy to discuss his presentation as part of the session on Controversies in Rheumatology that has as its focus the complexities of first-line targeted therapies for axial spondyloarthritis which is more commonly called (axSpA). He outlines how advanced therapies work differently in managing axSpA and what factors rheumatologists consider when deciding which of these medications should be used first for a patient with axSpA. He concludes by recommending how patients can work with their health care providers to ensure they receive the most effective treatment for their axSpA.
Resources
• Spondyloarthritis Research Consortium of Canada - https://sparcc.ca/
• Arthritis Consumer Experts’ About Axial Spondyloarthritis page – http://bit.ly/ACEAboutaxSpAEN
• A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition - https://pmc.ncbi.nlm.nih.gov/articles...
• Janus Kinases Inhibitors: A new tool for the treatment of axial spondyloarthritis - https://www.mdpi.com/1422-0067/24/2/1027
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
